Skip to main content
欧

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2026-04-14 Annual Report
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
2025年年度报告摘要
Annual Report Classification · 1% confidence The document is titled '年度报告摘要' (Annual Report Summary) for the company '成都欧康医药股份有限公司' (Chengdu Okay Pharmaceutical Co., Ltd.) for the year 2025. It contains key financial data, shareholding structures, and management information. While it is a summary, it serves as the official disclosure of the annual financial results and business status, which falls under the category of an Annual Report (10-K) in the context of financial reporting standards, as it provides the substantive financial data and management overview required for annual performance assessment. FY 2025
2026-04-14 Chinese
关于2024年股权激励计划回购注销部分限制性股票及调整回购价格的公告
Transaction in Own Shares Classification · 1% confidence The document is a formal corporate announcement by Chengdu Oukang Pharmaceutical Co., Ltd. detailing the board’s approval and execution of a targeted repurchase and cancellation of restricted shares under its 2024 equity incentive plan, including pricing adjustments, quantities, funding sources, capital reduction, and impact on share structure. This is a transaction in the company’s own shares under an employee incentive scheme. According to our taxonomy, such buyback and cancellation notices fall under “Transaction in Own Shares” (POS).
2026-04-14 Chinese
独立董事专门会议关于2024年股权激励计划回购注销部分限制性股票及调整回购价格的核查意见
Transaction in Own Shares Classification · 1% confidence The document is an official announcement by Chengdu Oukeang Medical’s independent directors regarding the company’s repurchase and cancellation of restricted stock under its 2024 equity incentive plan, including adjustments to the repurchase price. This clearly describes a corporate buyback of its own shares. According to our taxonomy, corporate share buybacks or sales by the company itself fall under “Transaction in Own Shares” (Code: POS).
2026-04-14 Chinese
关于召开2025年年度股东会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of the 2025 Annual General Meeting, including meeting date/time, agenda items (twelve proposals), voting procedures (onsite and online), shareholder registration rules and proxy authorization forms. This constitutes proxy solicitation materials sent to shareholders to provide meeting information and request voting instructions. Hence it best matches Proxy Solicitation & Information Statement (PSI).
2026-04-14 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 1% confidence The document is an announcement of the company’s formal “Remuneration Management System for Directors and Senior Management,” detailing compensation principles, structure, approval procedures, and related governance measures. This aligns with the specific category for compensation of top executives and directors rather than a general governance report. Hence, it is classified as Remuneration Information (DEF 14A).
2026-04-14 Chinese
内部控制审计报告
Audit Report / Information Classification · 1% confidence The document is a standalone internal control audit report issued by a registered accounting firm for the fiscal year ending December 31, 2025. It contains audit scope, responsibilities, and an audit opinion on the effectiveness of internal controls. It is not a full annual report, earnings release, or management discussion, but clearly an audit report. Therefore, it falls under Audit Report / Information (AR).
2026-04-14 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.